Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
about
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteers.Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
P2860
Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of the pharmacokine ...... Humira(®) in healthy subjects.
@en
Comparison of the pharmacokine ...... Humira(®) in healthy subjects.
@nl
type
label
Comparison of the pharmacokine ...... Humira(®) in healthy subjects.
@en
Comparison of the pharmacokine ...... Humira(®) in healthy subjects.
@nl
prefLabel
Comparison of the pharmacokine ...... Humira(®) in healthy subjects.
@en
Comparison of the pharmacokine ...... Humira(®) in healthy subjects.
@nl
P2093
P2860
P356
P1476
Comparison of the pharmacokine ...... Humira(®) in healthy subjects.
@en
P2093
Elizabeth Hyland
Martin Ullmann
Neil Attkins
Pantelis Vlachos
Sanjeev Roy
Volker Wagner
P2860
P304
P356
10.1111/BCP.13039
P407
P577
2016-06-10T00:00:00Z